Can Zytronic plc Beat AstraZeneca plc In 2016?

Zytronic plc (LON: ZYT) and AstraZeneca plc (LON: AZN) both have long-term growth potential

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Judging by yesterday’s full-year results release, Zytronic (LSE: ZYT) is trading well.

Compared to a year ago, revenue is up 13%, pre-tax profit up 39% and net cash from operations up around 17%. The directors marked this achievement by pumping up the dividend by 20% — nice!

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

On a roll

The British manufacturer makes interactive touch sensor products for things such as automatic transaction machines (ATMs), bill payment and financial information kiosks, vending machines and other commercial or industrial applications where humans interact with machines.

Although based and manufacturing from three modern factories in Blaydon upon Tyne in the UK, most of Zytronic’s production ships abroad — isn’t that wonderful! The firm works hard to improve its regional routes to market and established a technical support hub in the US in 2014. Now with eyes on the Greater China Region, Zytronic plans to set up what it calls a business- development and sales-opportunity-generation hub somewhere in Asia.

Such moves encourage me to believe that the firm has great potential for further growth from here.

The company’s recent financial record is good:

Year to September




Revenue (£m)




Pre-tax profit (£m)




Net cash from operations (£m)




Rising revenue is generating a healthy percentage of profit and it is all backed up with solid cash flow from operations. During 2015, Zytronic further bolstered its already-strong balance sheet by adding £2 million to its cash reserves.


Today’s 415p share price puts the firm on a forward price-to-earnings (P/E) multiple of just over 16 for 2016. The forward dividend yield comes in at 2.9%, and City analysts following the firm expect forward earnings to grow 3% that year and to cover the payout more than twice.

That valuation does look up with events, but the long-term potential for Zytronic is attractive. The firm deserves a place on my watch list, and any share-price weakness from here could be an opportunity to buy better value.

Building potential

Pitching Zytronic against AstraZeneca (LSE: AZN) makes it difficult to predict which of the two firms will do better for investors during 2016. AstraZeneca’s development pipeline is a potential powerhouse for new best-selling drugs and could hit the jackpot at any time. On top of that, the pharmaceutical giant operates an acquisition strategy that serves to reassure me that the firm remains serious about growth.

At today’s 4440p share price, AstraZeneca trades on a forward P/E rating of just under 17 for 2016 and there is a dividend yield of around 4.4% for investors to collect while waiting for any future growth spurt to kick in.

On balance, both Zytronic and AstraZeneca ooze with longer-term potential and maybe both would sit well in a portfolio with a five-year-plus investment horizon. That’s why I’m keeping an eye on both firms and may hit the ‘buy’ button on any temporary setback that knocks either firm’s share price.

More on Investing Articles

Portrait of construction engineers working on building site together
Investing Articles

Is this FTSE 100 stock the best housebuilder to invest in?

One FTSE 100 housebuilding stock has outperformed all of its industry peers by a big margin this year. Should I…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

2 cheap dividend growth stocks I’d buy as the economy sinks

I'm searching for the best bargains to buy following recent market volatility. Here are two top dividend growth stocks I…

Read more »

estate agent welcoming a couple to house viewing
Investing Articles

Here’s 1 FTSE stock primed to benefit from the current housing market!

With the current housing market as it is, Jabran Khan explores a related FTSE stock that could provide stable and…

Read more »

Portrait of construction engineers working on building site together
Investing Articles

Here’s why this AIM-listed stock could be one of the best shares to buy!

This Fool is looking for the best shares to buy. Despite macroeconomic issues, this stock could be a great long-term…

Read more »

Elderly father and adult son work in the garden
Investing Articles

This penny stock could be set to soar! Should I buy shares?

This Fool looks closely at a penny stock operating in an exciting growth market that could see its shares rise…

Read more »

Illustration of bull and bear
Investing Articles

The next stock market recovery looks imminent

As the stock market bear gives way to the bull, some stocks are already turning up and I'm ready to…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

2 dividend shares to protect me from soaring inflation

Dividend shares can be an excellent way to keep up with inflation. Our writer explores several options to protect his…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is it time to buy Unilever stock?

Unilever stock has underperformed in the last five years. But with its portfolio of powerful brands, should I buy now…

Read more »